On November 2, 2023 Vincerx Pharma, Inc. (Nasdaq: VINC)("Vincerx"), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, reported that it will present three posters related to VIP943 (NCT06034275), VIP924 (in preclinical studies), and enitociclib (in collaboration with University of Calgary) at the 65th American Society for Hematology Meeting (ASH) (Free ASH Whitepaper), taking place in San Diego California from December 9 to 12, 2023 (Press release, Vincerx Pharma, NOV 2, 2023, View Source [SID1234636801]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"The three ASH (Free ASH Whitepaper) 2023 posters highlight the strong scientific foundation for Vincerx’s programs. We look forward to providing new data on the robust preclinical activity of our lead antibody-drug conjugate (ADC), VIP943, which recently began enrolling patients with relapsed/refractory acute myeloid leukemia (R/R AML), myelodysplastic syndrome (MDS), and B-cell acute lymphoblastic leukemia (B-cell ALL)," said Ahmed Hamdy, M.D., Chief Executive Officer of Vincerx. "In addition, we are pleased to share preclinical data related to the activity of VIP924, a first-in-class CXCR5 ADC for the treatment of B-cell malignancies. Also, in collaboration with University of Calgary, we show enitociclib’s preclinical activity in pediatric leukemia."
Poster Presentation Information:
Title: Selectivity and Safety of VIP943: A Novel CD123-Targeting Antibody-Drug Conjugate (ADC) Using a Proprietary Linker and Payload Class
Session Name: 604. Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms: Poster I
Session Date: Saturday, December 9, 2023
Presentation Time: 5:30 PM – 7:30 PM, Pacific Standard Time
Location: San Diego Convention Center, Halls G-H
Publication Number: 1435
Presented by Beatrix Stelte-Ludwig, Vincerx Pharma
Title: Comparison of the CXCR5-Antibody Drug Conjugate (ADC; VIP924) to a CD19-ADC and a CD79b-ADC in a Humanized Rec-1 Mantle Cell Lymphoma (MCL) Mouse Model
Session Name: 605. Molecular Pharmacology and Drug Resistance: Lymphoid Neoplasms: Poster II
Session Date: Sunday, December 10, 2023
Presentation Time: 6:00 PM – 8:00 PM, Pacific Standard Time
Location: San Diego Convention Center, Halls G-H
Publication Number: 2809
Presented by Tibor Schomber, Vincerx Pharma
Title: Targeting CDK9 in KMT2A-Rearranged Infant Leukemia: Evidence for Activity and Drug Synergy with Enitociclib
Session Name: 616. Acute Myeloid Leukemias: Investigational Therapies, Excluding Transplantation and Cellular Immunotherapies: Poster III
Session Date: Monday, December 11, 2023
Presentation Time: 6:00 PM – 8:00 PM, Pacific Standard Time
Location: San Diego Convention Center, Halls G-H
Publication Number: 4293
Presented by Ritul Sharma, University of Calgary